Gautam Sanyal

Principal Consultant Vaccine Analytics

After receiving his Ph.D. in Chemistry from the University of Virginia, USA, Gautam held academic faculty positions at the University of Florida, Mayo Clinic and Hamilton College before moving to pharmaceutical industry. During the 27 years that Gautam spent in pharmaceutical industry, he headed R&D departments and groups at Merck, AstraZeneca and MedImmune (AstraZeneca Biopharmaceuticals). For the past several years, Gautam has focused his efforts on global health initiatives. He is a CMC Subject Matter Expert with the Gates Foundation and has been associated with other global health organizations such as CEPI, PATH and the International Vaccine Institute. Gautam is a scientific expert in development of analytical and biophysical methods that are essential to batch release and characterization of vaccines and biopharmaceuticals. His expertise extends to rational formulation design, as demonstrated by delivery of several safe and effective formulations to clinical trials for recombinant protein based VLPs and attenuated viral vaccines as well as therapeutic proteins and oncolytic viruses. More recently, Gautam has been involved in advisory roles on projects emerging from the newer vaccine technologies, with a focus on analytical characterization and assays for mRNA vaccines. Apart from his extensive work on vaccines and biologics, Gautam led biochemistry, biophysics and protein science teams in target-based discovery of antibacterial therapeutics. He has an extensive record of highly cited publications including original research papers, review articles and book chapters.

Seminars

Tuesday 29th September 2026
Leveraging Novel Biophysical & Analytical Techniques to Improve mRNALNP Process Consistency & Product Quality
12:00 pm
  • Utilizing emerging single-particle analysis techniques to complement ensemble analysis and detect heterogeneity in mRNA loading into LNPs, mRNA-LNP size, and cell transfection efficiency
  • Improving characterization to feedback into into mRNA-LNP manufacturing processes to optimize process conditions, reduce empty LNP populations and enhance overall product consistency
  • Establishing characterization-based improvement of process consistency and product quality to reduce dose requirement and improve safety profile of enhanced mRNALNP potency, to inform more robust, scalable and purification-aware CMC strategies
Gautam Sanyal speaker for 5th mRNA Process Development & CMC Summit